Cargando…

The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow

BACKGROUND: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. Urotensin II (UII) is an important vascular peptide, which has an important role in hypertension, coronary artery disease, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Şatıroğlu, Ömer, Durakoğlugil, Murtaza Emre, Çetin, Mustafa, Çiçek, Yüksel, Erdoğan, Turan, Duman, Hakan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Akadémiai Kiadó 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283774/
https://www.ncbi.nlm.nih.gov/pubmed/28180005
http://dx.doi.org/10.1556/1646.8.2016.4.1
_version_ 1782503548317073408
author Şatıroğlu, Ömer
Durakoğlugil, Murtaza Emre
Çetin, Mustafa
Çiçek, Yüksel
Erdoğan, Turan
Duman, Hakan
author_facet Şatıroğlu, Ömer
Durakoğlugil, Murtaza Emre
Çetin, Mustafa
Çiçek, Yüksel
Erdoğan, Turan
Duman, Hakan
author_sort Şatıroğlu, Ömer
collection PubMed
description BACKGROUND: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. Urotensin II (UII) is an important vascular peptide, which has an important role in hypertension, coronary artery disease, and vascular remodeling in addition to potent vasoconstrictor effect. OBJECTIVES: We investigated UII levels, hypertension, and other atherosclerotic risk factors in patients with SCF, a variety of coronary artery disease. METHODS: We enrolled 14 patients with SCF and 29 subjects with normal coronary arteries without SCF. We compared the UII levels and the atherosclerotic risk factors between patients with SCF and control subjects with normal coronary flow. RESULTS: UII concentrations were significantly higher in patients with SCF compared to controls (711.0 ± 19.4 vs. 701.5 ± 27.2 ng/mL, p = 0.006). We detected a positive correlation between SCF and age (r = 0.476, p = 0.001), BMI (r = 0.404, p = .002), UII concentrations (r = 0.422, p = 0.006), and hypertension (r = 0.594, p = 0.001). CONCLUSION: We identified increased UII levels in patients with SCF. We think that UII concentrations may be informative on SCF pathogenesis due to relationship with inflammation, atherosclerosis, and vascular remodeling.
format Online
Article
Text
id pubmed-5283774
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Akadémiai Kiadó
record_format MEDLINE/PubMed
spelling pubmed-52837742017-02-08 The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow Şatıroğlu, Ömer Durakoğlugil, Murtaza Emre Çetin, Mustafa Çiçek, Yüksel Erdoğan, Turan Duman, Hakan Interv Med Appl Sci Original Paper BACKGROUND: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. Urotensin II (UII) is an important vascular peptide, which has an important role in hypertension, coronary artery disease, and vascular remodeling in addition to potent vasoconstrictor effect. OBJECTIVES: We investigated UII levels, hypertension, and other atherosclerotic risk factors in patients with SCF, a variety of coronary artery disease. METHODS: We enrolled 14 patients with SCF and 29 subjects with normal coronary arteries without SCF. We compared the UII levels and the atherosclerotic risk factors between patients with SCF and control subjects with normal coronary flow. RESULTS: UII concentrations were significantly higher in patients with SCF compared to controls (711.0 ± 19.4 vs. 701.5 ± 27.2 ng/mL, p = 0.006). We detected a positive correlation between SCF and age (r = 0.476, p = 0.001), BMI (r = 0.404, p = .002), UII concentrations (r = 0.422, p = 0.006), and hypertension (r = 0.594, p = 0.001). CONCLUSION: We identified increased UII levels in patients with SCF. We think that UII concentrations may be informative on SCF pathogenesis due to relationship with inflammation, atherosclerosis, and vascular remodeling. Akadémiai Kiadó 2016-12-29 2016-12 /pmc/articles/PMC5283774/ /pubmed/28180005 http://dx.doi.org/10.1556/1646.8.2016.4.1 Text en © 2016 The Author(s) http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited.
spellingShingle Original Paper
Şatıroğlu, Ömer
Durakoğlugil, Murtaza Emre
Çetin, Mustafa
Çiçek, Yüksel
Erdoğan, Turan
Duman, Hakan
The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow
title The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow
title_full The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow
title_fullStr The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow
title_full_unstemmed The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow
title_short The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow
title_sort role of urotensin ii and atherosclerotic risk factors in patients with slow coronary flow
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283774/
https://www.ncbi.nlm.nih.gov/pubmed/28180005
http://dx.doi.org/10.1556/1646.8.2016.4.1
work_keys_str_mv AT satırogluomer theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT durakoglugilmurtazaemre theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT cetinmustafa theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT cicekyuksel theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT erdoganturan theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT dumanhakan theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT satırogluomer roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT durakoglugilmurtazaemre roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT cetinmustafa roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT cicekyuksel roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT erdoganturan roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow
AT dumanhakan roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow